A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
Trial details
- Registry ID
- NCT05956626
- Phase
- Phase 2, Phase 3
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt DiseaseNCT05956626 | Ocugen | Phase 2, Phase 3 | Active not recruiting | 2026-09-28Estimated |
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |